For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent, Illuccix® ...

On 16 January 2026, Telix Pharmaceuticals announced that the first U.S. patient had been dosed in BiPASS, a Phase 3 trial ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

Telix announces that its prostate cancer PET imaging agent, Illuccix (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM for the ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...